Abstract
Empirical antifungal therapy has been shown to decrease the number of documented fungal infections in the setting of persistent fever during neutropenia. For decades, amphotericin B deoxycholate has been considered the agent of choice for first-line therapy in this setting. New antifungal agents associated with less toxicity, including the lipid formulations of amphotericin, voriconazole, and caspofungin, are now available and are considered to be suitable alternative first-line agents. In order to ensure appropriate therapy, however, the clinician must consider not only the differences between these antifungals but also patient-specific factors before initiating treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Pizzo PA, Robichaud KJ, Gill FA, et al.: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101–111.
EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668–672.
Hughes WT, Armstrong D, Bodey GP, et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730–751. Guideline outlining risk factors and the appropriate use of antimicrobial agents in the setting of unexplained fever in neutropenic patients.
Fleming RV, Kantarjian HM, Husni R, et al.: Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001, 40:511–520.
Wingard JR, White MH, Anaissie E, et al.: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155–1163.
Walsh TJ, Finberg RW, Arndt C, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764–771.
Perea S and Patterson TF: Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002, 35:1073–1080.
Amphocin® (amphotericin B) [prescribing information]. Kalamazoo, MI: Pharmacia; 2003.
VFEND® (voriconazole) [prescribing information]. New York, NY: Pfizer; 2005.
Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety, and efficacy. Drugs 2004, 64:1997–2020.
Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630–637.
Cancidas® (caspofungin acetate) [prescribing information]. Whitehouse Station, NJ: Merck; 2005.
Frothingham R: Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis 2002, 35:896–897.
Prentice HG, Hann IM, Herbrecht R, et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711–718.
Walsh TJ, Pappas P, Winston DJ, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225–234. This randomized trial compared voriconazole to liposomal amphotericin B for empirical antifungal therapy in the setting of febrile neutropenia. Voriconazole did not meet the predefined noninferiority criteria set forth in this trial. However, when examining individual elements of the composite score, both treatment arms were found to be similar and voriconazole was superior in reducing documented breakthrough fungal infections. These findings, coupled with a better safety profile, make voriconazole an appealing alternative agent.
Wingard JR: Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004, 39(Suppl 1):S38-S43.
Walsh TJ, Teppler H, Donowitz GR, et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391–1402. This randomized trial compared caspofungin to liposomal amphotericin B for empirical antifungal therapy in the setting of febrile neutropenia. Caspofungin was found to be as effective as and better tolerated than liposomal amphotericin B, showing that caspofungin is a suitable alternative agent for empirical antifungal therapy.
Ascioglu S, Rex JH, de Pauw B, et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7–14. This international consensus guideline defines invasive fungal infections. These criteria were established to be used in clinical and epidemiologic research, allowing for comparisons between studies and avoiding differences in definitions between individual study groups.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Corey, M. Modern antifungal therapy for neutropenic fever. Curr Hematol Malig Rep 1, 95–100 (2006). https://doi.org/10.1007/s11899-006-0029-0
Issue Date:
DOI: https://doi.org/10.1007/s11899-006-0029-0